PERRIGO Co plc

NOTE 17 -SEGMENT AND GEOGRAPHIC INFORMATION

During the first quarter of 2026, we implemented changes to our organizational structure and internal management reporting to better align with how the CODM evaluates segment performance and allocates resources going forward.

Our reporting segments are as follows:

Our Oral Care product category and Other product category, which includes our Dermacosmetics Business (through its April 30, 2026 divestment), are together disclosed as “All Other.” We have reflected this segment change in all historical periods presented.

In the first quarter of 2026, following changes to our segments, our CODM reevaluated and changed the primary measure utilized to evaluate segment profitability from segment operating income to segment adjusted operating income. We have reflected this change from segment operating income to segment adjusted operating income in all historical periods presented.

For each segment, the CODM uses this information to assist in evaluating underlying trends, to monitor budget and forecast versus actual results, to make investment decisions to allocate resources both in total, and between the segments, and to make key segment personnel decisions. Segment adjusted operating income is based on Operating income, excluding amortization expense, acquisition and integration-related charges and contingent consideration, impairment charges, Infant Formula remediation, (gain) loss on divestitures and brand sales, loss on debt extinguishment, unusual litigation, and restructuring charges and other termination benefits (referred to herein as “Segment adjusted operating income (loss)”), as the CODM excludes these items in assessing segment financial performance. General corporate/unallocated expenses, which include expenses related to treasury, legal operations, and certain other expenses are not allocated to the segments. In assessing segment performance and managing operations, the CODM reviews total inventory by segment but does not review segment assets in total, accordingly certain asset related disclosures are omitted.

Note 17

The tables below show select financial measures by reporting segment(1) (in millions):

(3) Segment adjusted cost of sales represents costs of sales attributable to the reporting segments, excluding $28.6 million of amortization expense related primarily to acquired intangible assets and $2.5 million of accelerated depreciation related to Nutrition Network Optimization included in Other within the reconciliation to Income from continuing operations before income taxes.

(4) Segment adjusted operating expense items include distribution, research and development, and selling and administrative expenses, excluding $27.1 million of unusual litigation, $16.1 million of amortization expense related primarily to acquired intangible assets, $4.1 million related to impairment charges and a reversal of $1.5 million related to restructuring charges and other termination benefits.

(5) All Other segment adjusted operating income includes earnings from other operating segments of $26.6 million which excludes $9.7 million of amortization expense related primarily to acquired intangible assets and a reversal of $1.0 million related to restructuring charges and other termination benefits.

(6) Unallocated expense of $34.2 million excludes $13.9 million related to unusual litigation, $4.0 million related to professional consulting fees for potential divestiture activity and $2.5 million related to restructuring charges and other termination benefits.

(8) During the three months ended September 26, 2026, we determined the carrying value of our Medgenix business exceeded its estimated fair value less costs to sell, resulting in a total impairment charge of $4.1 million.

(11) Other pre-tax adjustments impacting operating income for the three months ended September 26, 2026 includes $4.1 million of professional consulting fees for potential divestitures and $2.5 million of accelerated depreciation as part of Nutrition Network Optimization.

Note 17

(3) Segment adjusted cost of sales represents costs of sales attributable to the reporting segments, excluding $90.1 million of amortization expense related primarily to acquired intangible assets and $21.2 million of accelerated depreciation related to Nutrition Network Optimization included in Other within the reconciliation to Income from continuing operations before income taxes.

(4) Segment adjusted operating expense items include distribution, research and development, and selling and administrative expenses, excluding $148.7 million related to impairment charges, $69.8 million related to restructuring charges and other termination benefits $51.1 million of unusual litigation, $47.7 million of amortization expense related primarily to acquired intangible assets and $0.4 million related to professional consulting fees.

(5) All Other segment adjusted operating income includes earnings from other operating segments of $84.1 million which excludes $187.2 million of impairment charges, $25.5 million of amortization expense related primarily to acquired intangible assets and a reversal of $1.3 million related to restructuring charges and other termination benefits.

(6) Unallocated expense of $101.4 million excludes $21.1 million related to restructuring charges and other termination benefits, $18.7 million related to unusual litigation and $12.1 million related to professional consulting fees for potential divestiture activity.

(8) During the nine months ended September 26, 2026, we determined the carrying value of our reporting units, Medgenix business and an in-process R&D asset exceeded their estimated fair value and recorded impairment charges of $330.8 million, $4.1 million, and $1.0 million respectively. Refer to Note 8 for details.

(11) Other pre-tax adjustments impacting operating income for the nine months ended September 26, 2026 includes $21.2 million of accelerated depreciation as a result of Nutrition Network Optimization and $12.5 million of professional consulting fees for potential divestiture activity and other legal matters.

Note 17

(3) Segment adjusted cost of sales represents costs of sales attributable to the reporting segments, excluding $28.5 million of amortization expense related primarily to acquired intangible assets and $4.0 million of accelerated depreciation related to Nutrition Network Optimization included in Other within the reconciliation to Income from continuing operations before income taxes.

(4) Segment adjusted operating expense items include distribution, research and development, and selling and administrative expenses, excluding $17.7 million of amortization expense related primarily to acquired intangible assets, $14.8 million related to restructuring charges and other termination benefits, a $1.6 million asset abandonment charge related to Nutrition Network Optimization included in Other within the reconciliation to Income from continuing operations before income taxes and $1.1 million of unusual litigation.

(5) All Other segment adjusted operating income includes earnings from other operating segments of $22.5 million which excludes $9.9 million of amortization expense related primarily to acquired intangible assets.

(6) Unallocated expense of $36.4 million excludes $13.9 million related to unusual litigation, $6.0 million related to restructuring charges and other termination benefits and $3.1 million related to professional consulting fees for divestiture activity included in Other within the reconciliation to Income from continuing operations before income taxes.

(8) Refer to Note 14 for details.

(9) Refer to Note 16 for details.

(10) Other pre-tax adjustments impacting operating income for the three months ended September 27, 2025 includes $4.0 million of accelerated depreciation and a $1.6 million asset abandonment charge related to Nutrition Network Optimization and $3.1 million related to professional consulting fees for divestiture activity.

(3) Segment adjusted cost of sales represents costs of sales attributable to the reporting segments, excluding $88.5 million of amortization expense related primarily to acquired intangible assets and $8.4 million of accelerated depreciation related to Nutrition Network Optimization included in Other within the reconciliation to Income from continuing operations before income taxes and $0.9 million of infant formula remediation.

(4) Segment adjusted operating expense items include distribution, research and development, and selling and administrative expenses, excluding $53.4 million of amortization expense related primarily to acquired intangible assets, $45.0 million related to restructuring charges and other termination benefits, $4.6 million of impairment charges, a $1.6 million asset abandonment charge related to Nutrition Network Optimization included in Other within the reconciliation to Income from continuing operations before income taxes and $1.6 million of unusual litigation.

(5) All Other segment adjusted operating income includes earnings from other operating segments of $69.0 million which excludes $25.9 million of amortization expense related primarily to acquired intangible assets.

(6) Unallocated expense of $114.8 million excludes $37.7 million related to unusual litigation, $14.0 million related to restructuring charges and other termination benefits and $8.5 million related to professional consulting fees for divestiture activity included in Other within the reconciliation to Income from continuing operations before income taxes.

(8) During the nine months ended September 27, 2025, we determined the carrying value of the Richard Bittner Business net assets held for sale exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million and we determined the carrying value of our Prevacid®branded product was impaired by $1.5 million.

Note 17

(11) Other pre-tax adjustments impacting operating income for the nine months ended September 27, 2025 includes $8.5 million of professional consulting fees for divestiture activity and $8.4 million of accelerated depreciation and a $1.6 million asset abandonment charge related to Nutrition Network Optimization.

The tables below show select financial measures by reporting segment(1) (in millions):